News archive
Showing 692 results
February 2016
-
Media Release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,… -
Media Release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
January 2016
-
Media Release
Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications… -
Media Release
Novartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
December 2015
-
Media Release
Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements… -
Media Release
Novartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
-
Media Release
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on… -
Media Release
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
-
Media Release
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
- Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma- Successful technology transfer enabling commercial scale-up of CTL019 cell… -
Media Release
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
November 2015
-
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
Novartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will be… -
Media Release
Novartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York